Sustained-release eye pharmaceutical Ocular Therapeutix files for a $86 million IPO


Shutterstock photo

Ocular Therapeutix, which develops and markets eye therapeutics using its sustained-release hydrogel platform, filed on Friday with the SEC to raise up to $86 million in an initial public offering. The Bedford, MA-based company, which was founded in 2006 and began selling its first product in February, plans to list on the NASDAQ under the symbol OCUL. Ocular Therapeutix initially filed confidentially on April 29, 2014. Morgan Stanley, Cowen & Company and RBC Capital Markets are the joint bookrunners on the deal. No pricing terms were disclosed.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.



This article appears in: News Headlines , IPOs


More from Renaissance Capital

Subscribe






Renaissance Capital
Contributor:

Renaissance Capital

IPOs
Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com